ASO Visual Abstract: A Prospective Multicenter Comparative Cohort Study of Neoadjuvant Sintilimab Plus Chemotherapy and Chemoradiotherapy in Resectable Clinical Node-Positive Esophageal Squamous Cell Carcinoma.

Rusidanmu A, Zhou K, Zhu X, Zheng D, Tu Z, Jiang H, Yang R, Liu K, Zhang H, Ye X, Yu H, Yu H, Xu P, Zhi S, Jing J, Wu X, Wu G, Peng C, Peng X, Huang B, Zheng Y, Ye P

Open source

DOI: 10.1245/s10434-026-20276-1
Published: 2026 Oct
Container: Annals of surgical oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1245/s10434-026-20276-1,
  title = {ASO Visual Abstract: A Prospective Multicenter Comparative Cohort Study of Neoadjuvant Sintilimab Plus Chemotherapy and Chemoradiotherapy in Resectable Clinical Node-Positive Esophageal Squamous Cell Carcinoma.},
  author = {Rusidanmu A and Zhou K and Zhu X and Zheng D and Tu Z and Jiang H and Yang R and Liu K and Zhang H and Ye X and Yu H and Yu H and Xu P and Zhi S and Jing J and Wu X and Wu G and Peng C and Peng X and Huang B and Zheng Y and Ye P},
  year = {2026},
  journal = {Annals of surgical oncology},
  doi = {10.1245/s10434-026-20276-1},
  url = {https://doi.org/10.1245/s10434-026-20276-1}
}

RIS

TY  - JOUR
TI  - ASO Visual Abstract: A Prospective Multicenter Comparative Cohort Study of Neoadjuvant Sintilimab Plus Chemotherapy and Chemoradiotherapy in Resectable Clinical Node-Positive Esophageal Squamous Cell Carcinoma.
AU  - Rusidanmu A
AU  - Zhou K
AU  - Zhu X
AU  - Zheng D
AU  - Tu Z
AU  - Jiang H
AU  - Yang R
AU  - Liu K
AU  - Zhang H
AU  - Ye X
AU  - Yu H
AU  - Yu H
AU  - Xu P
AU  - Zhi S
AU  - Jing J
AU  - Wu X
AU  - Wu G
AU  - Peng C
AU  - Peng X
AU  - Huang B
AU  - Zheng Y
AU  - Ye P
PY  - 2026
JO  - Annals of surgical oncology
DO  - 10.1245/s10434-026-20276-1
UR  - https://doi.org/10.1245/s10434-026-20276-1
ER  -

APA

A, R., K, Z., X, Z., D, Z., Z, T., H, J., R, Y., K, L., H, Z., X, Y., H, Y., H, Y., P, X., S, Z., J, J., X, W., G, W., C, P., X, P., B, H., Y, Z., & P, Y. (2026). ASO Visual Abstract: A Prospective Multicenter Comparative Cohort Study of Neoadjuvant Sintilimab Plus Chemotherapy and Chemoradiotherapy in Resectable Clinical Node-Positive Esophageal Squamous Cell Carcinoma.. Annals of surgical oncology. https://doi.org/10.1245/s10434-026-20276-1

Source records

pubmed · retrieved 2026-09-26T23:58:31.192Z